- Home
- NVS vs PM Comparison
NVS vs PM Comparison
Compare NVS & PM Stocks: Price Trends, ML Decisions, Charts, Trends, Technical Analysis and more.
Current Price
Current Price
Company Overview
Basic Information| Metric | NVS | PM |
|---|---|---|
| Founded | 1895 | 1987 |
| Country | Switzerland | United States |
| Employees | N/A | N/A |
| Industry | Biotechnology: Pharmaceutical Preparations | Medicinal Chemicals and Botanical Products |
| Sector | Health Care | Health Care |
| Exchange | Nasdaq | Nasdaq |
| Market Cap | 266.5B | 249.5B |
| IPO Year | 1991 | N/A |
Fundamental Metrics
Financial Performance| Metric | NVS | PM |
|---|---|---|
| Price | $141.96 | $155.46 |
| Analyst Decision | Hold | Strong Buy |
| Analyst Count | 5 | 9 |
| Target Price | $118.00 | ★ $190.44 |
| AVG Volume (30 Days) | 1.5M | ★ 5.9M |
| Earning Date | 01-30-2026 | 02-05-2026 |
| Dividend Yield | 1.82% | ★ 3.79% |
| EPS Growth | N/A | ★ N/A |
| EPS | ★ 7.30 | 5.52 |
| Revenue | ★ $56,372,000,000.00 | $39,992,000,000.00 |
| Revenue This Year | $9.38 | $10.75 |
| Revenue Next Year | $2.69 | $7.80 |
| P/E Ratio | ★ $19.49 | $28.10 |
| Revenue Growth | ★ 12.88 | 7.45 |
| 52 Week Low | $97.39 | $116.12 |
| 52 Week High | $142.58 | $186.69 |
Technical Indicators
Market Signals| Indicator | NVS | PM |
|---|---|---|
| Relative Strength Index (RSI) | 71.49 | 45.22 |
| Support Level | $135.55 | $160.28 |
| Resistance Level | $139.45 | $162.15 |
| Average True Range (ATR) | 1.57 | 2.83 |
| MACD | 0.24 | -0.51 |
| Stochastic Oscillator | 80.03 | 17.86 |
Price Performance
Historical ComparisonAbout NVS Novartis AG
Novartis develops and manufactures innovative drugs. Key areas of drug development include oncology, rare diseases, neuroscience, immunology, respiratory, cardio-metabolic, and established medicines. The company sells its products globally, with the United States comprising close to one third of total revenue.
About PM Philip Morris International Inc
Created from the international operations of Altria in 2008, Philip Morris International sells cigarettes and reduced-risk products, including heat sticks, vapes, and oral nicotine offerings, primarily outside of the US. With the 2023 acquisition of Swedish Match, a leading manufacturer of traditional oral tobacco products and nicotine pouches primarily in the US and Scandinavia, PMI is not only dominant in smokable products but also has the Iqos and Zyn brands, which respectively dominate heated tobacco and nicotine pouches in most markets.